Who
Brent Ness
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Aclarion.
In numbers
- Trades disclosed
- 13
- Buys
- 6
- Sells
- 0
- Bought
- $78K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 21 Apr 2022
- Last trade
- 13 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 17 Aug 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $12K5,234 at $2.31 | filing |
| 13 Aug 2026filed 17 Aug 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $12K5,234 at $2.31 | filing |
| 11 Jun 2026filed 12 Jun 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $20K6,289 at $3.18 | filing |
| 11 May 2026filed 11 May 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $20K6,289 at $3.18 | filing |
| 26 Nov 2025filed 1 Dec 2025 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $6210 at $6.20 | filing |
| 29 Dec 2022filed 29 Dec 2022 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $4,3358,500 at $0.51 | filing |
| 29 Dec 2022filed 29 Dec 2022 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $4,4727,711 at $0.58 | filing |
| 28 Dec 2022filed 29 Dec 2022 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $9612,289 at $0.42 | filing |
| 15 Sep 2022filed 15 Sep 2022 | ACON Aclarionoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —75,582 at $0.00 | filing |
| 21 Apr 2022filed 25 Apr 2022 | ACON Aclarionoption or derivative · Diagnostics & Labs | SEC FORM 4 Code P | —1,000 at $0.00 | filing |
| 21 Apr 2022filed 25 Apr 2022 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $4,3501,000 at $4.35 | filing |
News
Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar DiscsACON · manilatimes.net · 22 Oct 2026Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026ACON · manilatimes.net · 20 Oct 2026
0 headlines in the last 90 days name Brent Ness; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.